Gordon A. Brown, DO

In this video, Gordon A. Brown, DO, FACOS, offers perspective on integrating PTEN testing and AKT inhibition into evolving biomarker-driven treatment strategies for mHSPC.

Gordon A. Brown, DO, FACOS, summarizes overall survival trends, safety findings, and clinical considerations for managing adverse events with dual pathway inhibition.

In this video, Gordon A. Brown, DO, FACS, explores post hoc analyses from CAPItello-281 evaluating increasing PTEN deficiency thresholds and their relationship to treatment response.

Gordon A. Brown, DO, FACOS, reviews rPFS outcomes demonstrating clinical benefit with capivasertib plus abiraterone in PTEN-deficient mHSPC.

In this video, Gordon A. Brown, DO, FACOS, discusses PTEN deficiency as a prognostic marker and its implications for treatment selection, monitoring, and risk stratification in mHSPC.

Gordon A. Brown, DO, FACOS, gives an overview of PTEN biology, distinctions between PTEN loss and deficiency, and the clinical importance of PI3K/AKT pathway activation in prostate cancer progression.

Looking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.

The panel concludes by offering key takeaways on the evolving treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer.

Experts on non–muscle invasive bladder cancer discuss promising developments in the overall treatment landscape, highlighting potentially practice-changing clinical research.

Experts on prostate cancer discuss the benefits to multidisciplinary care as it pertains to PSMA-PET imaging.

Prostate cancer specialists discuss challenges associated with imaging in clinical practice.

Bladder cancer specialists discuss their strategies for monitoring patients with BCG-unresponsive non–muscle invasive bladder cancer.

A panel of experts provide clinical insights on factors that inform how they select treatments for patients with BCG-unresponsive non–muscle invasive bladder cancer.

A panel of experts on prostate cancer share strategies for monitoring patients and discuss whether to use PSMA to monitor treatment response.

Experts on prostate cancer discuss the ideal timing and frequency of PSMA-PET imaging and the role of different PSMA-PET agents.

Focusing on active surveillance of patients with prostate cancer, discussion centers around the role of PSMA-PET imaging and the implications of negative scans.

The panel discusses how PSMA-PET imaging informs treatment decisions for patients with prostate cancer.

Experts on bladder cancer discusses strategies to minimize adverse effects and the role of immunotherapy in BCG-unresponsive NMIBC treatment paradigms.

Bladder cancer experts discuss quality of life and progression considerations and their impact on treatment decisions for patients with BCG-unresponsive NMIBC.

Steven Finkelstein, MD, FACRO, discusses PSMA-PET imaging practices for patients experiencing biochemical recurrence.

Experts on prostate cancer offer clinical insights on identifying the appropriate patients for PSMA-PET imaging.

Jason Hafron, MD, CMO, provides an overview of the QUILT trial investigating N-803 in patients with BCG-unresponsive high-grade non–muscle invasive bladder cancer.

The panel reviews data from the SunRISe-1 trial investigating TAR-200 and offers its impressions on the efficacy and safety findings.

The panel discusses the role of PSMA-PET imaging in prostate cancer and highlights different PSMA agents.

Bladder cancer experts discuss the evolving treatment landscape in BCG-unresponsive NMIBC and give an overview of TAR-200, an emerging therapy.

A panel of experts on prostate cancer provide an overview of conventional imaging modalities that have been used in the initial staging and management of prostate cancer and discuss the role of PSMA-PET imaging.

A panel of experts on non–muscle invasive bladder cancer (NMIBC) discuss challenges associated with BCG shortages and the impact on treatment options and patients’ quality of life.

Dr Gordon Brown closes his discussion on mCSPC by highlighting unmet needs in the field and ongoing initiatives that may address these needs.

A comparison of the safety and efficacy of available AR inhibitors and a discussion of factors that impact treatment selection in mCSPC.

Gordon A. Brown, DO, comments on adverse events observed after combination ADT/apalutamide treatment and how they might be managed.